secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001683168-26-003205
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test
--------------------------------------------------------------------------------

- Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
- BreastCheck is a non-invasive, 15-minute test for breast abnormalities, registered with FDA, EU, and UK regulators.
- Global breast cancer screening market estimated at $26B; commercial sales expected to begin in H2 2026.
- CEO Michael Redmond says agreement provides clear pathway to near-term revenue and supports growth strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/0001683168-26-003205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer